Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Roland, Buelow"'
Autor:
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Kristin Lewis Wilson, Harbani K. Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Rodolfovan D. Yabut, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein, Katherine E. Harris
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy t
Externí odkaz:
https://doaj.org/article/9e96f15bb0a54d7bb137adf3be604c3c
Autor:
Harshad S. Ugamraj, Kevin Dang, Laure-Hélène Ouisse, Benjamin Buelow, Eduardo N. Chini, Giulia Castello, James Allison, Starlynn C Clarke, Laura M. Davison, Roland Buelow, Rong Deng, Suhasini Iyer, Ute Schellenberger, Sankar N. Manika, Shipra Bijpuria, Astrid Musnier, Anne Poupon, Maria Cristina Cuturi, Wim van Schooten, Pranjali Dalvi
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Cluster of differentiation 38 (CD38) is an ecto-enzyme expressed primarily on immune cells that metabolizes nicotinamide adenine dinucleotide (NAD+) to adenosine diphosphate ribose or cyclic ADP-ribose and nicotinamide. Other substrates of CD38 inclu
Externí odkaz:
https://doaj.org/article/fdbba7fafcb24832b1853db840f82f25
Autor:
Katherine E. Harris, Kyle J. Lorentsen, Harbani K. Malik-Chaudhry, Kaitlyn Loughlin, Harish Medlari Basappa, Sharon Hartstein, Ghenima Ahmil, Nicole S. Allen, Brian C. Avanzino, Aarti Balasubramani, Andrew A. Boudreau, Karen Chang, Maria-Cristina Cuturi, Laura M. Davison, Dennis M. Ho, Suhasini Iyer, Udaya S. Rangaswamy, Preethi Sankaran, Ute Schellenberger, Roland Buelow, Nathan D. Trinklein
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy o
Externí odkaz:
https://doaj.org/article/6280e71ffa694c31a509b1afcf87bff2
Autor:
Lawrence Fong, Serena Kwek, Rong Deng, Yuping Li, Kevin Dang, Giulia Castello, Starlynn C Clarke, Aarti Balasubramani, Andrew Boudreau, Laura Davison, Katherine E Harris, Duy Pham, Preethi Sankaran, Harshad S Ugamraj, Alec Starzinski, Suhasini Iyer, Wim van Schooten, Ute Schellenberger, Wenchao Sun, Nathan D Trinklein, Roland Buelow, Ben Buelow, Pranjali Dalvi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent
Externí odkaz:
https://doaj.org/article/b008929f34b84d778350eb4e4a7bcce4
Autor:
Harbani K. Malik-Chaudhry, Kirthana Prabhakar, Harshad S. Ugamraj, Andrew A. Boudreau, Benjamin Buelow, Kevin Dang, Laura M. Davison, Katherine E. Harris, Brett Jorgensen, Heather Ogana, Duy Pham, Ute Schellenberger, Wim Van Schooten, Roland Buelow, Suhasini Iyer, Nathan D. Trinklein, Udaya S. Rangaswamy
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents,
Externí odkaz:
https://doaj.org/article/54c6dadc1dc04e3c82d81639cfba9a39
Autor:
Francesca Ros, Sonja Offner, Stefan Klostermann, Irmgard Thorey, Helmut Niersbach, Sebastian Breuer, Grit Zarnt, Stefan Lorenz, Juergen Puels, Basile Siewe, Nicole Schueler, Tajana Dragicevic, Dominique Ostler, Imke Hansen-Wester, Valeria Lifke, Brigitte Kaluza, Klaus Kaluza, Wim van Schooten, Roland Buelow, Alain C Tissot, Josef Platzer
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Transgenic animals incorporating human antibody genes are extremely attractive for drug development because they obviate subsequent antibody humanization procedures required for therapeutic translation. Transgenic platforms have previously been estab
Externí odkaz:
https://doaj.org/article/eb4cfd37c8a244a096d64b9303c73a7f
Autor:
Starlynn C. Clarke, Biao Ma, Nathan D. Trinklein, Ute Schellenberger, Michael J. Osborn, Laure-Hélène Ouisse, Andrew Boudreau, Laura M. Davison, Katherine E. Harris, Harshad S. Ugamraj, Aarti Balasubramani, Kevin H. Dang, Brett Jorgensen, Heather Anne N. Ogana, Duy T. Pham, Payal P. Pratap, Preethi Sankaran, Ignacio Anegon, Wim C. van Schooten, Marianne Brüggemann, Roland Buelow, Shelley Force Aldred
Publikováno v:
Frontiers in Immunology, Vol 9 (2019)
Heavy chain-only antibodies (HCAbs) do not associate with light chains and their VH regions are functional as single domains, forming the smallest active antibody fragment. These VH regions are ideal building blocks for a variety of antibody-based bi
Externí odkaz:
https://doaj.org/article/6a706cdfcb4649ab82279f4b31c5c13b
Autor:
Katherine E. Harris, Shelley Force Aldred, Laura M. Davison, Heather Anne N. Ogana, Andrew Boudreau, Marianne Brüggemann, Michael Osborn, Biao Ma, Benjamin Buelow, Starlynn C. Clarke, Kevin H. Dang, Suhasini Iyer, Brett Jorgensen, Duy T. Pham, Payal P. Pratap, Udaya S. Rangaswamy, Ute Schellenberger, Wim C. van Schooten, Harshad S. Ugamraj, Omid Vafa, Roland Buelow, Nathan D. Trinklein
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
We created a novel transgenic rat that expresses human antibodies comprising a diverse repertoire of heavy chains with a single common rearranged kappa light chain (IgKV3-15-JK1). This fixed light chain animal, called OmniFlic, presents a unique syst
Externí odkaz:
https://doaj.org/article/0e55864017b746d182977ff0f5e8bf28
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Autor:
Harshad Ugamraj, Shelley Force Aldred, Katherine E. Harris, Suhasini Iyer, Brett Jorgensen, Payal Pratap, Ute Schellenberger, Kevin Dang, Nathan D. Trinklein, Omid Vafa, Starlynn Clarke, Udaya Rangaswamy, Duy Pham, Andrew Boudreau, Arun P. Wiita, Wim Van Schooten, Roland Buelow, Ben Buelow, Priya Choudhry
Publikováno v:
mAbs
T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. The use of novel anti-CD3 binding domains with more favorable properti
Autor:
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Harbani Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein, Katherine E. Harris
Publikováno v:
Cancer Research. 82:6244-6244
The use of T cell engagers (TCEs) to treat solid tumors in humans is challenging, and several have been limited by narrow therapeutic windows due to substantial toxicity. Dose-limiting toxicities of TCEs include cytokine release syndrome (CRS) and on